文献速递免疫规划

在登革热非流行国家联合接种减毒四价登革热疫苗(TAK-003)与灭活甲型肝炎病毒疫苗的免疫原性和安全性的随机3期试验

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.
PubMed 文献 · Vaccine · 2023-01-19

这项在英国的随机、观察者盲法3期试验将900名18-60岁健康成人按1:1:1分为三组,评估甲肝疫苗与TAK-003联合接种的免疫原性和安全性。结果显示,联合接种组第30天甲肝血清保护率(98.7%)非劣于单独接种组(97.1%),差异为-1.68(95%CI:-8.91至4.28);第120天90.9%-96.8%的TAK-003受种者对四个登革血清型均呈血清阳性。联合接种耐受良好,未发现重要安全性风险。

要点

  • 联合接种组第30天甲肝血清保护率98.7%,非劣于单独接种组的97.1%。
  • 第120天90.9%-96.8%的TAK-003受种者对四个登革血清型均血清阳性。
  • 联合接种耐受良好,未发现重要安全性风险。

核心结论

  • 甲肝疫苗与TAK-003联合接种后的免疫应答非劣于单独接种甲肝疫苗,结果支持两者联合接种且对任一疫苗的免疫原性、安全性和反应原性无不良影响。

研究设计与样本

  • 随机、观察者盲法3期试验,在英国纳入900名18-60岁健康成人,按1:1:1随机分为三组。
  • 第1组:第1天接种甲肝疫苗和安慰剂,第90天接种安慰剂;第2组:第1天接种TAK-003和安慰剂,第90天接种TAK-003;第3组:第1天接种TAK-003和甲肝疫苗,第90天接种TAK-003。
  • 主要目标为在甲肝未感染且登革未感染参与者中,第3组第30天甲肝血清保护率(抗-HAV ≥ 12.5 mIU/mL)相对于第1组的非劣效性。

主要发现

  • 第30天,联合接种组(第3组)甲肝血清保护率为98.7%,单独接种组(第1组)为97.1%,差异为-1.68(95%CI:-8.91至4.28)。
  • 第30天抗-HAV几何平均浓度:第1组为82.1(95%CI:62.9-107.1)mIU/mL,第3组为93.0(95%CI:76.1-113.6)mIU/mL。
  • 截至第120天,90.9%-96.8%的TAK-003受种者对四个登革血清型均呈血清阳性(中和抗体滴度 > 10)。
  • 联合接种耐受良好,未发现重要安全性风险。

关键数值与推荐

  • 甲肝血清保护率第3组98.7% vs 第1组97.1%,差异-1.68(95%CI:-8.91至4.28),符合非劣效性。
  • 第30天抗-HAV几何平均浓度第1组82.1(95%CI:62.9-107.1)mIU/mL,第3组93.0(95%CI:76.1-113.6)mIU/mL。
  • 第120天对四个登革血清型血清阳性(中和抗体滴度 > 10)的比例范围为90.9%-96.8%。

临床怎么用

  • 原文结论认为结果支持甲肝疫苗与TAK-003联合接种,且对任一疫苗的免疫原性、安全性和反应原性无不良影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination against hepatitis A virus (HAV) is largely recommended for travelers worldwide. Concurrent dengue and HAV vaccination may be desired in parallel for travelers to countries where both diseases are endemic. This randomized, observer-blind, phase 3 trial evaluated coadministration of HAV vaccine with tetravalent dengue vaccine (TAK-003) in healthy adults aged 18-60 years living in the UK. METHODS: Participants were randomized (1:1:1) to receive HAV vaccine and placebo on Day 1, and placebo on Day 90 (Group 1), TAK-003 and placebo on Day 1, and TAK-003 on Day 90 (Group 2), or TAK-003 and HAV vaccine on Day 1, and TAK-003 on Day 90 (Group 3). The primary objective was non-inferiority of HAV seroprotection rate (anti-HAV ≥ 12.5 mIU/mL) in Group 3 versus Group 1, one month post-first vaccination (Day 30) in HAV-naïve and dengue-naïve participants. Sensitivity analyses were performed on combinations of baseline HAV and dengue serostatus. Secondary objectives included dengue seropositivity one month post-second vaccination (Day 120), HAV geometric mean concentrations (GMCs), and safety. RESULTS: 900 participants were randomized. On Day 30, HAV seroprotection rates were non-inferior following coadministration of HAV and TAK-003 (Group 3: 98.7 %) to HAV administration alone (Group 1: 97.1 %; difference: -1.68, 95 % CI: -8.91 to 4.28). Sensitivity analyses including participants who were neither HAV-naïve nor DENV-naïve at baseline supported this finding. Anti-HAV GMCs on Day 30 were 82.1 (95 % CI: 62.9-107.1) mIU/mL in Group 1 and 93.0 (76.1-113.6) mIU/mL in Group 3. By Day 120, 90.9-96.8 % of TAK-003 recipients were seropositive (neutralizing antibody titer > 10) to all four dengue serotypes. Coadministration of HAV vaccine and TAK-003 was well tolerated, with no important safety risks identified. CONCLUSION: Immune responses following coadministration of HAV vaccine and TAK-003 were non-inferior to administration of HAV vaccine alone. The results support the coadministration of HAV vaccine and TAK-003 with no adverse impact on immunogenicity, safety, and reactogenicity of either vaccine. CLINICALTRIALS: gov registration: NCT03525119.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tricou V, Eyre S, Ramjee M, et al. A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. Vaccine. 2023. PMID: 36681529. doi:10.1016/j.vaccine.2023.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。